KDx Diagnostics has collaborated with UroGPO, a Specialty Networks Company, to offer a non-invasive urine test, URO17, to detect bladder cancer in the US.
The research use only (RUO) test can be used to determine the status of active bladder cancer and help improve patient diagnosis.
It is currently available in the US as a Laboratory Developed Test (LDT). This enables the test to improve the treatment path.
Under the partnership, UroGPO will provide the members of its Group Purchasing Organisation network with reagents and information for the URO17 test.
KDx Diagnostics president Sholeh Jahanfard said: “We are very excited to partner with UroGPO, the premier urology network and group purchasing organisation in the US, to make our URO17 test and information available to their network of clinical laboratories.
“Through UroGPO, the urology laboratories will have direct access to ordering with a special in-network pricing which will facilitate the availability of URO17 to the urologists.”
With high sensitivity and negative predicted value (NPV) features, the urine test will help eliminate the need for unnecessary cystoscopy and invasive procedures in patients with bladder cancer.
According to the company, more than 85,000 new bladder cancer cases a year are reported in the US.
Hematuria, or blood in the urine, is the most common symptom of bladder cancer, and patients may need invasive cystoscopic procedures.
Specialty Networks Contracting senior director Palmer DePetro said: “The URO17 test adds efficiency and precision to the care of patients with bladder cancer.
“KDx has taken steps to remove barriers of access for both physicians and patients, which will ultimately benefit patient outcomes, improve quality of life and even mortality.”